Fidelity Investments’s INmune Bio INMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$65.6K Sell
33,624
-65
-0.2% -$134 ﹤0.01% 4228
2026
Q2
$54.9K Buy
33,689
+20,099
+148% +$27.8K ﹤0.01% 4273
2026
Q1
$15.4K Sell
13,590
-507
-4% -$722 ﹤0.01% 4617
2025
Q4
$22K Buy
14,097
+10,926
+345% +$19.5K ﹤0.01% 4422
2025
Q3
$6.56K Buy
3,171
+661
+26% +$1.51K ﹤0.01% 4714
2025
Q2
$5.8K Sell
2,510
-463
-16% -$3.4K ﹤0.01% 4678
2025
Q1
$23.2K Buy
2,973
+1,344
+83% +$10.7K ﹤0.01% 4170
2024
Q4
$7.61K Buy
1,629
+205
+14% +$1.07K ﹤0.01% 4548
2024
Q3
$7.68K Buy
1,424
+1,339
+1,575% +$9.5K ﹤0.01% 4513
2024
Q2
$750 Sell
85
-500
-85% -$4.93K ﹤0.01% 4827
2024
Q1
$6.87K Buy
585
+500
+588% +$6.04K ﹤0.01% 4406
2023
Q4
$957 Hold
85
– – ﹤0.01% 4754
2023
Q3
$581 Hold
85
– – ﹤0.01% 4699
2023
Q2
$772 Sell
85
-7
-8% -$56 ﹤0.01% 4752
2023
Q1
$594 Buy
92
+83
+922% +$668 ﹤0.01% 4779
2022
Q4
$57 Buy
+9
New +$64 ﹤0.01% 4928

Other funds holding INMB

Fidelity Investments's INMB Position: Q3 2026 in Review

Fidelity Investments reduced its INmune Bio (INMB) stake by 0.19% in Q3 2026, selling an estimated $134 and leaving 33,624 shares worth $65.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4228.

Fidelity Investments first reported a position in INMB in Q4 2022 and has held it in 16 quarters since. 63 funds tracked by Wall St. Rank hold INMB as of Q3 2026.

  • Fidelity Investments held 33,624 shares of INmune Bio worth $65.6K as of Q3 2026.
  • Fidelity Investments sold 65 INmune Bio shares in Q3 2026, an estimated $134.
  • INmune Bio made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #4228 holding.
  • Fidelity Investments first reported a position in INmune Bio in Q4 2022 and has held it in 16 quarters since.
  • 63 funds tracked by Wall St. Rank held INmune Bio as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.